Carillon Tower Advisers’s Heron Therapeutics HRTX Stock Holding History

Carillon Tower Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,274,695	Closed	-$23.7M	–	480
2019 Q2	$23.7M	Hold	1,274,695	–	–	0.16%	224
2019 Q1	$31.2M	Hold	1,274,695	–	–	0.22%	170
2018 Q4	$33.1M	Hold	1,274,695	–	–	0.28%	138
2018 Q3	$40.3M	Hold	1,274,695	–	–	0.29%	138
2018 Q2	$49.5M	Hold	1,274,695	–	–	0.39%	82
2018 Q1	$33.7M	Buy	+1,274,695	New	+$28.9M	0.26%	131

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Carillon Tower Advisers's HRTX Position: Q3 2019 in Review

Carillon Tower Advisers sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 1,274,695 shares — an estimated $23.7M sold.

Carillon Tower Advisers first reported a position in HRTX in Q1 2018 and held it in 6 quarters. The position peaked at $49.5M in Q2 2018. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

Carillon Tower Advisers reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
Carillon Tower Advisers sold 1,274,695 Heron Therapeutics shares in Q3 2019, an estimated $23.7M.
Carillon Tower Advisers first reported a position in Heron Therapeutics in Q1 2018 and held it in 6 quarters.
Carillon Tower Advisers's Heron Therapeutics position peaked at $49.5M in Q2 2018.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Carillon Tower Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.